Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma

被引:2
作者
Uemura, Suguru [1 ]
Mori, Takeshi [1 ]
Ishiko, Shinya [1 ]
Takafuji, Satoru [1 ]
Nino, Nanako [1 ]
Yamamoto, Nobuyuki [1 ]
Hayakawa, Akira [2 ]
Nishimura, Noriyuki [1 ]
Hara, Hitomi [3 ]
Kawamoto, Teruya [3 ]
Akisue, Toshihiro [3 ]
Iijima, Kazumoto [1 ]
机构
[1] Kobe Univ, Dept Pediat, Grad Sch Med, Kobe, Hyogo, Japan
[2] Yodogawa Christians Hosp, Dept Palliat Med, Osaka, Japan
[3] Kobe Univ, Dept Orthpaed Surg, Grad Sch Med, Kobe, Hyogo, Japan
关键词
Autologous stem cell transplantation; high-dose chemotherapy; osteosarcoma; HIGH-GRADE OSTEOSARCOMA; PROGNOSTIC-FACTORS; PREOPERATIVE CHEMOTHERAPY; EXTREMITIES; THERAPY; RESCUE;
D O I
10.1080/08880018.2020.1729906
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The outcomes of osteosarcoma with poor prognostic factors, such as poor responders, metastatic disease at diagnosis, and relapsed or refractory disease, are poor. We reviewed the clinical records of the patients diagnosed with osteosarcoma at our institute between 2004 and 2018 who received high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in our institute. Ten patients of osteosarcoma with poor responder, refractory status, and metastatic disease at diagnosis received high-dose chemotherapy followed by ASCT. Four patients underwent high-dose chemotherapy followed by ASCT with the conditioning regimen consisted of thiotepa and melphalan (MEL). Five patients underwent high-dose chemotherapy followed by ASCT with the conditioning regimen consisted of intravenous busulfan (BU) and MEL. One patient underwent tandem high-dose chemotherapy followed by ASCT with BU and MEL followed by carboplatin and etoposide. None of the ten patients died of regimen related toxicities. None of the five patients with poor responders who underwent high-dose chemotherapy followed by ASCT as part of consolidation therapy died of disease after ASCT. High-dose chemotherapy followed by ASCT might be effective for poor responders in osteosarcoma.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 18 条
[1]   Autologous stem cell transplantation in solid tumours of childhood [J].
Atra, A ;
Pinkerton, CR .
ANNALS OF MEDICINE, 1996, 28 (02) :159-164
[2]   Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity - Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor [J].
Bacci, G ;
Bertoni, F ;
Longhi, A ;
Ferrari, S ;
Forni, C ;
Biagini, R ;
Bacchini, P ;
Donati, D ;
Manfrini, M ;
Bernini, G ;
Lari, S .
CANCER, 2003, 97 (12) :3068-3075
[3]   Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].
Bielack, SS ;
Kempf-Bielack, B ;
Delling, G ;
Exner, GU ;
Flege, S ;
Helmke, K ;
Kotz, R ;
Salzer-Kuntschik, M ;
Werner, M ;
Winkelmann, W ;
Zoubek, A ;
Jürgens, H ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790
[4]   High-Dose Chemotherapy with Stem Cell Rescue in the Primary Treatment of Metastatic and Pelvic Osteosarcoma: Final Results of the ISG/SSG II Study [J].
Boye, Kjetil ;
Del Prever, Adalberto Brach ;
Eriksson, Mikael ;
Saeter, Gunnar ;
Tienghi, Amelia ;
Lindholm, Paula ;
Fagioli, Franca ;
Skjeldal, Sigmund ;
Ferrari, Stefano ;
Hall, Kirsten Sundby .
PEDIATRIC BLOOD & CANCER, 2014, 61 (05) :840-845
[5]   High-dose chemotherapy in the treatment of relapsed osteosarcoma: An Italian sarcoma group study [J].
Fagioli, F ;
Aglietta, M ;
Tienghi, A ;
Ferrari, S ;
del Prever, AB ;
Vassallo, E ;
Palmero, A ;
Biasin, E ;
Bacci, G ;
Picci, P ;
Madon, E .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2150-2156
[6]   Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival [J].
Ferrari, S ;
Briccoli, A ;
Mercuri, M ;
Bertoni, F ;
Picci, P ;
Tienghi, A ;
Del Prever, AB ;
Fagioli, F ;
Comandone, A ;
Bacci, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :710-715
[7]   High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma [J].
Hong, C. R. ;
Kang, H. J. ;
Kim, M. S. ;
Ju, H. Y. ;
Lee, J. W. ;
Kim, H. ;
Kim, H-S ;
Park, S-H ;
Park, K. D. ;
Park, J. D. ;
Shin, H. Y. ;
Ahn, H. S. .
BONE MARROW TRANSPLANTATION, 2015, 50 (10) :1375-1378
[8]   Osteosarcoma: Current Treatment and a Collaborative Pathway to Success [J].
Isakoff, Michael S. ;
Bielack, Stefan S. ;
Meltzer, Paul ;
Gorlick, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (27) :3029-U127
[9]   Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].
Kanda, Y. .
BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458
[10]  
Lee Ji Won, 2008, Cancer Res Treat, V40, P172, DOI 10.4143/crt.2008.40.4.172